CBDNewsBreaks Archive - Page 34 of 278

FridayApr 09, 2021 1:21 pm

CBDNewsBreaks – Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) Targets Investments that Complement, Further Business Goals

Pac Roots (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), an innovative genetics-based cannabis company located in Canada, recently acquired a large tract of land (250 acres) in one of Canada’s most productive and intensively farmed areas. “The company is also in the process of completing its 20,000-square-foot cultivation facility in Lake County, B.C., that will allow it to cycle through an elite line of high-grade cultivars across roughly 7,600 square feet of cultivation space,” reads an article discussing Pac Roots’ recent moves. The land and cultivation facility are part of a growing list of investments, given that the company recently completed…

ThursdayApr 08, 2021 1:25 pm

CBDNewsBreaks – Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) Closes on Majority Ownership of Plant-Based CBD Skincare Brand

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF), a premier, consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, has closed on the purchase of its majority ownership in Fifth & Root Inc., a California-based, nationally recognized CBD skin-care brand. Fifth & Root noted that it hopes the move will allow the company to provide innovative CBD products nationwide through the largest and best beauty retail partners in the country. The purchase agreement noted that GLDFF will pay total consideration of up to $1,687,500 for 80% ownership of Fifth & Root. The consideration will consist of $250,000 cash payment…

ThursdayApr 08, 2021 10:11 am

CBDNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Releases Q4, FY 2020 Audited Financial Report

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp-branded products company in the United States, has released audited financial and operational results for fourth-quarter and fiscal year periods ending Dec. 31, 2020. Financial highlights from the report include an increase in gross profits of 104% in 2020, totaling $5.6 million in 2020 compared to $2.8 million in 2019; cash balance of $11.6 million; an increase in net revenues of 15% from 2019, with 2020 totals reaching $15.9 million; and a 67% improvement in operating costs. The company also noted several key new product launches throughout the year, including the…

WednesdayApr 07, 2021 9:31 am

CBDNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Launches CBD Product Line in Asia Through Tmall

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has received conditional approval to offer its proprietary CBD products on Tmall, the world’s largest cross-border online marketplace. This news follows the company’s recent announcement that its Probulin Probiotics would also be available on Alibaba Group Holding’s Tmall Global (“Tmall”). The third most-visited website in the world, Tmall represents more than 750 million potential new consumers living across mainland China, Hong Kong, Macau and Taiwan. The announcement noted that the site provides unique opportunities for HempFusion to raise…

MondayApr 05, 2021 2:22 pm

CBDNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Releases Operational Update, FY 2020 Results

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has released both an operational update and the filing of its annual and fourth-quarter financial results for the fiscal year ended December 31, 2020. Company highlights include being ranked no. 2 in Brightfield Group’s most recent survey in the CBD Brand Awareness (U.S.) category, as well as SPINS naming its proprietary Probulin Probiotics product fastest-growing probiotic brand in 2020 out of the top 10 in the country. Other highlights included being the no. 2 CBD holding in AdvisorShares…

FridayMar 26, 2021 1:58 pm

CBDNewsBreaks – RYAH Group Inc. Holds Key Distinction in Telehealth Era

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, appears ready to respond to strict data security requirements. This is an important distinction in an era where the use of telehealth solutions is exploding while securing the integrity of patient information remains critical. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) is U.S. legislation surrounding requirements for medical providers to integrate privacy and security provisions to safeguard their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain and it is. Therefore, it is…

ThursdayMar 25, 2021 1:14 pm

CBDNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Announces Completion of Pilot Trial, Releases White Paper

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has completed a pilot study assessing the effect of its HempFusion formulation CBD Capsules(R) (HempFusion 20mg CBD capsules with botanical terpenes) as it relates to a combination of anti-inflammatories in lowering the results of the chronic inflammation test. The study was conducted in collaboration with Kansas-based Inflammatory Markers Laboratory (“IML”). In addition, the company also released a white paper titled, “Oral Formulation May Modulate Thromboxane Production.” The white paper was s co-authored by IML director Gordon Ens and…

WednesdayMar 24, 2021 2:09 pm

CBDNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, as well as focusing on other potential pandemic biosensor tech…

WednesdayMar 24, 2021 12:13 pm

CBDNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Releases Q4 and FY 2020 Financial, Operational Report

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has announced its fourth-quarter and full-year numbers for the period ended Dec. 31, 2020. In the report, Willow noted that it had filed a short form base shelf prospectus that allowed the company to make offerings of securities of up to an aggregate of $50 million. The company also completed an overnight marketed public offering for gross proceeds of $11.5 million, which was upsized by $2.0 million and included the exercise of a 15% overallotment. In addition, Willow inked a deal with…

TuesdayMar 23, 2021 1:53 pm

CBDNewsBreaks – HempFusion Wellness Inc. (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) Announces Results from CBD Liver Safety Study Have Been Released

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has announced that Validcare released its initial findings from an industry-sponsored, decentralized, human-safety study of hemp-derived CBD products. Validcare is coordinating the execution of the study, which HempFusion was involved with. The study may be the largest human observational, liver and human toxicology study to date. According to HempFusion’s announcement, the seven-month-long study showed no evidence of liver toxicity in any of the 839 participants enrolled in the clinical trials; the company noted that the study results are…

News and publishing service for CBD related companies

Contact us: 512.354.7000

CannabisNewsBreaks